Groundbreaking technology to detect Alzheimer’s developedJanuary 7th, 2011 - 2:58 pm ICT by ANI
Washington, Jan 07 (ANI): A novel technology that is able to detect the presence of immune molecules specific to Alzheimer’s disease in patients’ blood samples has been developed by the scientists from the Florida campus of The Scripps Research Institute.
While still preliminary, the findings offer clear proof that this breakthrough technology could be used in the development of biomarkers for a range of human diseases.
The new study, challenges conventional wisdom and uses synthetic molecules rather than antigens to successfully detect signs of disease in patients’ blood samples.
These synthetic compounds have many advantages - they can be modified easily and can be produced quickly in relatively large amounts at lower cost.
To test the concept, Scripps Research Professor Thomas Kodadek and his colleagues used comparative screening of combinatorial libraries of synthetic molecules - peptoids - against serum samples obtained from mice with a multiple-sclerosis-like condition or healthy controls. Those synthetic molecules that retained more immunoglobulin (IgG), a major type of antibody, from the blood samples of the diseased animals were identified as potential agents for capturing diagnostically useful molecules. This worked well.
The team next turned to serum samples from six Alzheimer’s patients, six healthy individuals, and six Parkinson’s disease patients. Three peptoids were identified that captured at least three-fold higher levels of IgG antibodies from all six of the Alzheimer’s patients than any of the control or Parkinson’s patients. The results showed that two of the peptoids bind the same IgG antibodies; a third binds different antibodies, resulting in at least two candidate biomarkers for the disease.
“We use these peptoids as a lure to capture the IgG antibodies,” Kodadek said.
“Some of these synthetic molecules recognize the antigen-binding sites of disease-specific antibodies well enough to pull them from blood samples, although they almost certainly don’t bind as well as the native antigens. This ability should make it possible to short circuit the discovery of the natural antigens.”
The study has been published in the edition of the journal Cell. (ANI)
- Now, blood tests can detect Alzheimer's disease before symptoms occur - Feb 12, 2011
- Quick blood test for Alzheimer's detection in offing - Jan 07, 2011
- Trigger to early, effective antibody response discovered - Jul 07, 2010
- New device can detect infectious disease quickly - Mar 01, 2012
- Four novel biomarkers that may help diagnose asthma, COPD identified - Mar 12, 2011
- New antibodies to combat Alzheimer's - Dec 12, 2011
- Microsponges from seaweed may help diagnose diseases quickly - Feb 10, 2011
- Discovery enables quicker diagnosis of chikunguyna - Mar 15, 2012
- 'Bacterial rope, DNA chips to shape Indian biotech scene' - Sep 04, 2012
- Possible biomarker to gauge Alzheimer's prognosis identified - Mar 18, 2011
- Biomarkers in blood serum could classify individuals with Alzheimer's - Sep 14, 2010
- Umbilical cord blood not the right indicator to measure allergy risk - Oct 06, 2010
- New test hastens diagnosis of top cause of AIDS-related deaths - Mar 05, 2011
- Key Alzheimer's risk gene causes alterations in shapes of brain protein deposits - Jul 15, 2010
- Fat levels in blood may lead to Alzheimer's - Jul 19, 2012
Tags: antigens, biomarkers, blood samples, breakthrough technology, clear proof, combinatorial libraries, conventional wisdom, disease patients, diseased animals, florida campus, human diseases, igg antibodies, immunoglobulin, novel technology, professor thomas, research professor, scripps research institute, serum samples, synthetic compounds, synthetic molecules